Physician profile
Terry L Cable
NPI 1508120502
$1,323.05
in general payments reported to CMS, 2019-2025
18 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.51 · 2024: $80.85 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $186.08 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $181.33 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $149.93 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $148.48 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $139.04 | 2025 | Fanapt |
| Lundbeck LLC | $135.10 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $99.90 | 2025 | Azstarys |
| Biogen, INC. | $80.20 | 2025 | Zurzuvae |
| Indivior INC. | $40.71 | 2024 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $23.03 | 2025 | Uzedy |
| Braeburn INC. | $21.14 | 2024 | Brixadi |
| Neurocrine Biosciences, INC. | $20.56 | 2025 | |
| Supernus Pharmaceuticals, INC. | $17.44 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $17.28 | 2025 | Spravato |
| Axsome Therapeutics, INC. | $16.94 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.83 | 2025 | |
| Noven Therapeutics, LLC | $15.13 | 2025 | Xelstrym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.93 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Cable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.